Showing results (201-210 of 247) with videos related to
Sort By:
Pageof 25
British Journal of Cancer|September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancerMartin H Voss, Michael S Gordon, Monica Mita, et al.Advances in Therapy|October 26, 2013
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysisDenise A Yardley, Shinzaburo Noguchi, Kathleen I Pritchard, et al.Journal of Hepatology|May 17, 2025
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 studyDo-Youn Oh, Aiwu Ruth He, Shukui Qin, et al.European Journal of Cancer (Oxford, England : 1990)|January 23, 2016
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancerShubham Pant, Suzanne F Jones, Carla D Kurkjian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancerDavid Loesch, F Anthony Greco, Neil N Senzer, et al.Cancer|March 19, 2013
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trialHoward A Burris, Fabienne Lebrun, Hope S Rugo, et al.Clinical Breast Cancer|November 26, 2013
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2Kathleen I Pritchard, Howard A Burris, Yoshinori Ito, et al.Journal of the National Cancer Institute|February 22, 2013
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2Michael Gnant, Jose Baselga, Hope S Rugo, et al.Cancer|March 26, 2020
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA resultsSumanta K Pal, Dean Bajorin, Nazli Dizman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximabShirin Khambata-Ford, Christopher R Garrett, Neal J Meropol, et al.Pageof 25